IL2 and acute myeloid leukemia: Björklund et al. evaluated the administration of IL-2-activated haploidentical NK cells in primary relapsed/refractory (R/R) high-risk myelodysplastic syndrome (MDS), secondary AML (MDS/AML), and de novo AML patients.